Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Between 10% and 25% of newly diagnosed stage IIIB/stage IV patients currently receive single
agent chemotherapy regimens. A significant proportion of these patients will be elderly (70
years of age) and many oncologists would consider intravenous vinorelbine or gemcitabine to
be the standard of care in this patient population. It has been demonstrated that single
agent vinorelbine offers therapeutic advantages to selected NSCLC patients over best
supportive care alone.
Carboplatin plus Alimta have an acceptable toxicity profile and few clinical problems so it
could be acceptable its use in elderly patients.
A randomised study is being performed therefore to assess whether progression free survival,
the primary efficacy endpoint for this study, achieved with Carboplatin plus Alimta is
superior than achieved with gemcitabine, one of the current standards of care in elderly
patients with advanced NSCLC.